WallStSmart

Fresenius Medical Care Corporation (FMS)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 2142% more annual revenue ($19.63B vs $875.26M). NUTX leads profitability with a 8.1% profit margin vs 5.0%. NUTX trades at a lower P/E of 9.1x. FMS earns a higher WallStSmart Score of 62/100 (C+).

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 10.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.82

NUTX

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 9.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$90.32

Current Price

$22.26

$68.06 discount

UndervaluedFair: $90.32Overvalued
NUTXSignificantly Overvalued (-44.5%)

Margin of Safety

-44.5%

Fair Value

$71.26

Current Price

$100.38

$29.12 premium

UndervaluedFair: $71.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

NUTX4 strengths · Avg: 9.5/10
P/E RatioValuation
9.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
58.9%10/10

Every $100 of equity generates 59 in profit

Operating MarginProfitability
97.5%10/10

Strong operational efficiency at 97.5%

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

FMS4 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.2%4/10

4.2% earnings growth

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

NUTX3 concerns · Avg: 2.3/10
Market CapQuality
$671.69M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-41.1%2/10

Revenue declined 41.1%

EPS GrowthGrowth
-86.2%2/10

Earnings declined 86.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Return on Equity, Operating Margin.

Bear Case : FMS

The primary concerns for FMS are EPS Growth, Altman Z-Score, Return on Equity. Thin 5.0% margins leave little buffer for downturns.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

NUTX carries more volatility with a beta of 2.00 — expect wider price swings.

FMS is growing revenue faster at -0.3% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (62/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?